Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance

Current Opinion in Investigational Drugs

Volumn 11, Issue 8, 2010, Pages 901-910

  Grant, Philip M ^a   Zolopa, Andrew R ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Anti HIV agent; antiretroviral therapy; CCR5 antagonist; drug resistance; integrase inhibitor

Indexed keywords

1349572; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MYELOABLATIVE AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS DNA; ZIDOVUDINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DISEASE CARRIER; DRUG EFFICACY; DRUG POTENCY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LEUKEMIA; MYELOABLATIVE CONDITIONING; PHENOTYPE; PRACTICE GUIDELINE; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD;

EID: 77954983245     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 271(5255):1582-1586.
2. Preston BD, Poiesz BJ, Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science (1988) 242(4882):1168-1171.
3. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J et al: Identification of a reservoir of HIV-1 on highly active antiretroviral therapy. Science (1997) 278(5341):1295-1300.
4. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman MJ, Witek J, Kedanis RJ, Natkin J, DeSimone J, Pomerantz RJ: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 282(17):1627-1632.
5. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS: Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA (2008) 105(10): 3879-3884.
6. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, Coffin JM et al: Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 22(10):1131-1135.
7. Jones J, McMahon D, Wiegand A, Kearney M, Palmer S, McNulty S, Metcalf J, Coffin J, Mellors J, Maldarelli F: No decrease in residual viremia during raltegravir intensification in patients on standard ART. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2009) 16:Abs 423b.
8. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW et al: Longterm control of HIV by CCR5 Δ32/Δ32 stem-cell transplantation. N Engl J Med (2009) 360(7):692-698.
9. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 246(4934):1155-1158.
10. Sista P, Rinehart A, Wasikowski B, Winters B, Pattery T, Bacheler L: Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals. J Clin Virol (2009) 44(3):190-194.
11. von Wyl V, Yerly S, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Francioli P et al: Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis (2009) 48(7):979-987
12. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ et al: Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 49(10):1582-1590.
13. Young B, Johnson S, Bahktiari M, Shugarts D, Young RK, Allen M, Ramey RR 2nd, Kuritzkes DR: Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis (1998) 178(5): 1497-1501.
14. US Department of Health and Human Services HIV Guidelines: Department of Health and Human Services, Washington DC, USA (2009). www.aidsinfo.nih.gov/ Guidelines
15. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM et al: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 300(5):555-570.
16. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K et al: Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-nave patients: A randomized trial. JAMA (2004) 292(2):180-190.
17. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER et al: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-nave populations and associate with reduced treatment efficacy. PLoS Med (2008) 5(7):e158.
18. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Mancini M, Uy J, Seekins D, Krystal M, McGrath D, Simen B et al: Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-nave subjects in the CASTLE study. PLoS ONE (2010) 5(6):e10952.
19. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C et al: Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ (2005) 331(7259):1368.
20. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D et al: The epidemiology of antiretroviral drug resistance among drug-nave HIV-1-infected persons in 10 US cities. J Infect Dis (2004) 189(12):2174-2180.
21. Wheeler W, Mahle K, Bodnar U, Kline R, Hall I, McKenna M, the US Variant, Atypical and Resistant HIV Surveillance (VARHS) Group: Antiretroviral drug-resistance mutations and subtypes in drug-nave persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006.
22. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, UK Register of HIV Seroconverters: Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS (2007) 21(8):1035-1039.
23. Little S, Frost S, Smith D, May S, Parkin N, Richman D, Richman D: Transmission of HIV drug resistance and treatment response. Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA (2007) 14:Abs 60.
24. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kücherer C, Struck D, Schmit JC, Asjö B, Bruckova M et al: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 200(10):1503-1508.
25. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB et al: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 359(14):1429-1441.
26. Gathe J, Diaz R, Fatkenheuer G, Zeinecker J, Mak C, Vilchez R, Greaves W, Kumar S, Onyebuchi C, Dunkle L: Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2010) 17: Abs 54LB.
27. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T et al: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 194(7):926-930.
28. Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, van der Ryst E, Mayer H, A4001029 Study Group: A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis (2009) 199(11):1638-1647
29. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD et al: Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviralnave subjects with CCR5-tropic HIV-1 infection. J Infect Dis (2010) 201(6):803-813.
30. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E: Emergence of CXCR4- using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol (2006) 80(10):4909-4920.
31. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitorbound receptor for entry. J Virol (2007) 81(5):2359-2371.
32. Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP: Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci USA (2009) 106(13):5318-5323.
33. Sato A, Seki T, Kobayashi M, Yoshinaga T, Fujiwara T, Underwood M, Garvey E, Johns B: In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/ GSK1349572. ICAAC (2009) 49:Abs H-932/415.
34. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C et al: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 359(4):339-354.
35. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D et al: High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: Results of the ANRS 139 TRIO trial. Clin Infect Dis (2009) 49(9):1441-1449.
36. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ et al: Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-nave patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet (2009) 374(9692):796-806.
37. Gotuzzo E, Nguyen B-Y, Markowitz M, Mendo F, Ratanasuwan W, Lu C, Zhao J, Homony B, Barnard R, Teppler H, the Protocol 004 Part II study team: Sustained antiretroviral efficacy of raltegravir after 192 weeks of combination ART in treatmentnave HIV-1 infected patients. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2010) 17:Abs 514.
38. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK: Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: Results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis (2010) 201(6):814-822.
39. Cohen C, Shamblaw D, Ruane P, Elion R, DeJesus E, Liu H, Zhong L, Warren D, Kearney B, Chuck S: Single-tablet, fixed-dose regimen of elvitegravir/ emtricitabine/tenofovir disoproxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2010) 17:Abs 58LB.
40. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade- Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN et al: Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir- based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet (2010) 375(9712):396-407.
41. DeJesus E, Cohen C, Elion R, Ortiz R, Maroldo L, Franson S, Pesano R: First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137). IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia (2007) 4:Abs TUPEB032.
42. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H et al: Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet (2006) 368(9534): 466-475.
43. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M et al: Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet (2007) 370(9581):49-58.
44. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C et al: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet (2007) 369(9568): 1169-1178.
45. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T et al: Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-nave HIV-1-infected patients at week 48. AIDS (2008) 22(12):1389-1397.
46. Hill A, Moyle G: Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med (2007) 8(4):259-264.
47. Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A: Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: An independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother (2010) 54(6):2473-2479.
48. Chan-Tack KM, Struble KA, Birnkrant DB: Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ ritonavir: Review of cases from the FDA's Adverse Event Reporting System. AIDS Patient Care STDS (2008) 22(11): 843-850.
49. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B et al: Efficacy and safety of etravirine in treatmentexperienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials. AIDS (2009) 23(17):2289-2300.
50. Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J et al: Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother (2010) 54(1):72-77.
51. Pozniak A, Morales-Ramirez J, Mohapi L, Santoscoy M, Chetchotisakd P, Hereygers M, Vanveggel S, Peeters M, Woodfall B, Boven K: 48-Week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-nave patients. Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2008) 15:Abs 144LB.
52. Bauman JD, Das K, Baweja M, Clark A Jr, Boyer P, Shatkin A, Lewi P, Hughes S, Arnold E: Structures of HIV-1 reverse transcriptase complexed with NNRTI TMC278: Conformational and positional adaptability overcomes resistance mutations. Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2008) 15:Abs 88.
53. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N et al: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 359(14):1442-1455.
54. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M et al: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 359(4):355-365.
55. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ et al: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med (1999) 341(25):1865-1873.
56. Haubrich R, Schapiro JM, Vingerhoets J, Nijs S, Peeters M, De Smedt G, Woodfall B, de Béthune M, Picchio G: Combined darunavir and etravirine resistance analysis of the pooled DUET trials: When can we spare the other new classes? International AIDS Conference, Mexico City, Mexico (2008) 17: Abs TUPE0048.
57. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR: Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis (2005) 41(2):236-242.
58. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, Purdon S: The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS (2000) 14(7):781-789.
59. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF et al: Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med (2003) 139 (5 Pt 1):313-320.
60. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN: Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis (2005) 192(9):1537-1544.
61. Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG et al: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 47(2):266-285.
62. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res (2003) 31(1): 298-303.
63. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzàlez J, Domingo P, Boucher C, Rey-Joly C, Clotet B, Havana Study Group: Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS (2002) 16(2):209-218.
64. Sturt AS, Dokubo EK, Sint TT: Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev (2010) (3):CD008440.
65. Chang LW, Harris J, Humphreys E: Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Cochrane Database Syst Rev (2010) (4):CD008494.